Daclatasvir

Drug Profile

Daclatasvir

Alternative Names: BMS-790052; Daklinza; DCV

Latest Information Update: 10 Feb 2017

Price : $50

At a glance

  • Originator AmeriCares; Bristol-Myers Squibb
  • Developer Bristol-Myers Squibb; Vertex Pharmaceuticals
  • Class Antivirals; Biphenyl compounds; Carbamates; Imidazoles; Pyrrolidines; Small molecules
  • Mechanism of Action Hepatitis C virus NS 5 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hepatitis C

Most Recent Events

  • 02 Dec 2016 The EMA’s Pharmacovigilance Risk Assessment Committee issues a warning about the risk of hepatitis B-reactivation with direct-acting antiviral drugs, including daclatasvir
  • 28 Nov 2016 Daclatasvir sub-licensed to Mylan via Medicines Patent Pool for generic production for the treatment of Hepatitis C
  • 16 Apr 2016 Interim efficacy and adverse events data from the phase II COMMIT trial in Hepatitis C (Combination therapy, Treatment-naive) presented at The International Liver Congress™ 2016 (ILC 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top